Management of idiopathic pulmonary fibrosis: selected case reports

Kreuter, Michael; Kardos, Péter; Hoffstein, V.

doi:10.1183/09059180.00002014

Cited by 4 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kreuter et al presented a typical IP case with an extensive GGO in HRCT. Due to the unusual presentation of the patient, the diagnosis of typical IP was made with compatible pathological features in surgical lung biopsy [3]. In that case report, smoking was a triggering factor for ILD, and smoking cessation reduced GGO.…”

Section: Clinical Medicine Hypothesismentioning

confidence: 93%

“…In addition, groundglass opacities (GGO) can also be detected on highresolution computerized tomography (HRCT) in some typical IP patients. GGO, which is the main radiological feature of non-specific interstitial pneumonia (NSIP), may be a negative predictor of typical IP [3,4]. Here, this finding may affect the diagnostic algorithm and lead to surgical lung biopsy for diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ground Glass Opacities: Sign of Caution in Typical Interstitial Pneumonia

Tezcan

Kasman

2023

CAJMHE

View full text Add to dashboard Cite

Typical interstitial pneumonia (IP) is mainly the fibrotic form of interstitial lung disease. In some cases with typical IP, a certain amount of ground-glass opacity (GGO) can be detected on high-resolution computed tomography, however, some important issues, such as the co-existence of GGO and typical IP, still require further investigation by biopsy. After the diagnosis of typical IP, anti-fibrosis treatment is usually considered. Here, we hypothesized that GGO in typical IP could be a manifestation of an acute inflammatory attack requiring immunosuppressive therapy or an indicator of ongoing contact with trigger factors that initiate pathological reactions in typical IP.

show abstract

Section: Clinical Medicine Hypothesismentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Ground Glass Opacities: Sign of Caution in Typical Interstitial Pneumonia

Tezcan

Kasman

2023

CAJMHE

View full text Add to dashboard Cite

show abstract

“…The format of the reviews has also diversified over the past 3 years, with the introduction of case-based reviews [2] and of mini-reviews. A subset of the mini-reviews published focus on basic science or translational topics while others cover the proceedings from respiratory medicine conferences.…”

Section: A Success Storymentioning

confidence: 99%

The European Respiratory Review: farewell from the editor with confidence for the future

Cottin

2015

Eur Respir Rev

View full text Add to dashboard Cite

“…Pirfenidone has several effects that can be interpreted as being ‘antifibrotic'. Among others, it reduces the expression of collagen in fibroblast and muscle cells in vitro [80]. In 2 out of 3 phase 3 trials, pirfenidone significantly reduced the decline of the forced vital capacity in patients with idiopathic pulmonary fibrosis [76,81].…”

Section: Clinical Trials In Idiopathic Pulmonary Fibrosismentioning

confidence: 99%

“…It is an orally active, small molecule that inhibits the synthesis of profibrotic and inflammatory mediators. Chemically, pirfenidone is 5-methyl-1-phenylpyridin-2-one [80]. The precise mechanism of action of pirfenidone is still unknown.…”

Section: Clinical Trials In Idiopathic Pulmonary Fibrosismentioning

confidence: 99%

New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?

Rogler

2014

Dig Dis

View full text Add to dashboard Cite

Crohn's disease (CD) is characterized by the frequent occurrence of complications, such as fibrotic strictures and subsequently the need for CD-related surgery. Chronic or recurrent inflammation is generally regarded to be a necessary precondition for the initiation of intestinal fibrosis. In this view, fibrosis is a pathologically augmented healing response to inflammation-induced mucosal tissue destruction and injury. At present, there are no approved or effective medical therapies aimed specifically at fibrosis or stricture in IBD. Indirect benefits may occur from anti-inflammatory therapies, although there is no consensus on this. Therapy for fibrosis is complicated by the fact that a wound-healing response is essential in CD and ulcerative colitis. Several pharmaceutical companies are now working on the therapy of fibrosis in other diseases. Strategies interfering with TGF-β expression and activation are promising. Pirfenidone has been studied in several clinical trials. Further therapeutic options are second-generation and wide-spectrum tyrosine kinase inhibitors. These inhibit growth factor receptor signaling, thus reducing fibrosis in animal models and some patients with tumor-associated fibrosis. At present, the development of antifibrotic therapies takes place in other diseases such as lung and liver fibrosis. This is partially due to a lack of experimental models for gut fibrosis and the fact that reliable readouts (MRI, serum markers) in patients are lacking. It will be important to test the above-mentioned newly available treatment strategies in IBD to profit from progress in other fibrotic diseases.

show abstract

Management of idiopathic pulmonary fibrosis: selected case reports

Abstract: In

Cited by 4 publications

References 18 publications

Ground Glass Opacities: Sign of Caution in Typical Interstitial Pneumonia

Ground Glass Opacities: Sign of Caution in Typical Interstitial Pneumonia

The European Respiratory Review: farewell from the editor with confidence for the future

New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?

Contact Info

Product

Resources

About